Latest & greatest articles for amiodarone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on amiodarone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on amiodarone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for amiodarone

61. Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery. (Abstract)

Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery. Atrial fibrillation occurs commonly after open-heart surgery and may delay hospital discharge. The purpose of this study was to assess the use of preoperative amiodarone as prophylaxis against atrial fibrillation after cardiac surgery.In this double-blind, randomized study, 124 patients were given either oral amiodarone (64 patients) or placebo (60 patients) for a minimum of seven days before elective (...) cardiac surgery. Therapy consisted of 600 mg of amiodarone per day for seven days, then 200 mg per day until the day of discharge from the hospital. The mean (+/-SD) preoperative total dose of amiodarone was 4.8+/-0.96 g over a period of 13+/-7 days.Postoperative atrial fibrillation occurred in 16 of the 64 patients in the amiodarone group (25 percent) and 32 of the 60 patients in the placebo group (53 percent) (P=0.003). Patients in the amiodarone group were hospitalized for significantly fewer days

1997 NEJM Controlled trial quality: uncertain

62. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials

Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta (...) -analysis of individual data from 6500 patients in randomised trials Amiodarone Trials Meta-Analysis Investigators Authors' objectives To assess the benefits and risks of prophylactic amiodarone in patients with recent myocardial infarction (MI) or congestive heart failure (CHF). Searching The searches were described as a literature review, computerised literature search and discussion with colleagues. A collaborative group of principal investigators was established. Study selection Study designs

1997 DARE.

63. Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death

Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death Sim I, McDonald K M, Lavori P W, Norbutas C M, Hlatky M A Authors' objectives To assess the effect of amiodarone on mortality, and the impact of differences in patient population and study design on trial outcomes. Searching MEDLINE (...) and BIOSIS Previews were searched for all trials of amiodarone published between January 1985 and March 1997. The references of the retrieved articles and relevant conference proceedings were also examined. Professionals were contacted for additional trials. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) with at least 3 months treatment and follow-up were included. Specific interventions included in the review Amiodarone in doses ranging from 200

1997 DARE.

64. Adverse effects of low dose amiodarone: a meta-analysis

Adverse effects of low dose amiodarone: a meta-analysis Adverse effects of low dose amiodarone: a meta-analysis Adverse effects of low dose amiodarone: a meta-analysis Vorperian V R, Havighurst T C, Miller S, January C T Authors' objectives To assess the odds of experiencing adverse effects with low-dose amiodarone therapy when compared with placebo. Searching MEDLINE was searched through 1996 for trials published in all languages. Manual searches of references and review articles were also (...) carried out. Study selection Study designs of evaluations included in the review Double-blind placebo-controlled trials of maintenance amiodarone with a mean follow-up of at least 12 months [A: and presence of an explicit description of adverse effects in both intervention and placebo groups] were included. Crossover designs were excluded. Specific interventions included in the review Maintenance amiodarone (dose of less than or equal to 400 mg/day) and placebo. Participants included in the review

1997 DARE.

65. Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death

Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death Owens D K, Sanders G D, Harris R A, McDonald K M, Heidenreich P A, Dembitzer A D, Hlatky M A Record Status This is a critical (...) . Study population The study populations were hypothetical cohorts of patients at either high or intermediate risk of sudden cardiac death. The base-case analysis assumed patients were 57 years old and had survived previous cardiac arrest and thus were at high risk of sudden cardiac death. Patients were at risk for ventricular tachycardia or fibrillation, nonarrhythmic cardiac death, noncardiac death, illness or death related to amiodarone, and perioperative morbidity and mortality related to ICDs

1997 NHS Economic Evaluation Database.

66. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. (Abstract)

Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. Asymptomatic ventricular arrhythmias in patients with congestive heart failure are associated with increased rates of overall mortality and sudden death. Amiodarone is now used widely to prevent ventricular tachycardia and fibrillation. We conducted a trial to determine whether amiodarone can reduce overall mortality in patients (...) with congestive heart failure and asymptomatic ventricular arrhythmias.We used a double-blind, placebo-controlled protocol in which 674 patients with symptoms of congestive heart failure, cardiac enlargement, 10 or more premature ventricular contractions per hour, and a left ventricular ejection fraction of 40 percent or less were randomly assigned to receive amiodarone (336 patients) or placebo (338 patients). The primary end point was overall mortality, and the median follow-up was 45 months (range, 0 to 54

1995 NEJM Controlled trial quality: predicted high

67. Treatment of resistant atrial fibrillation: a meta-analysis comparing amiodarone and flecainide

Treatment of resistant atrial fibrillation: a meta-analysis comparing amiodarone and flecainide Treatment of resistant atrial fibrillation: a meta-analysis comparing amiodarone and flecainide Treatment of resistant atrial fibrillation: a meta-analysis comparing amiodarone and flecainide Zarembski D G, Nolan P E, Slack M K, Caruso A C Authors' objectives To compare the efficacies of two antiarrhythmic drug therapies, amiodarone hydrochloride and flecainide acetate, in maintaining normal sinus (...) rhythm in patients with resistant chronic atrial fibrillation. Searching Current Contents: Clinical Practice was reviewed and MEDLINE was searched from January 1983 to August 1993 for English language studies. Bibliographies of identified articles were searched to locate additional articles. Study selection Study designs of evaluations included in the review Prospective clinical trials were included. Specific interventions included in the review Amiodarone hydrochloride and flecainide acetate

1995 DARE.

68. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA) (Abstract)

Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA) In severe heart failure many deaths are sudden and are presumed to be due to ventricular arrhythmias. The GESICA trial evaluated the effect of low-dose amiodarone on two-year mortality in patients with severe heart failure. Our prospective multicentre trial included 516 patients on optimal standard treatment for heart failure. Patients (...) were randomised to 300 mg/day amiodarone (260) or to standard treatment (256). Intention-to-treat analysis showed 87 deaths in the amiodarone group (33.5%) compared with 106 in the control group (41.4%) (risk reduction 28%; 95% CI 4%-45%; log rank test p = 0.024). There were reductions in both sudden death (risk reduction 27%; p = 0.16) and death due to progressive heart failure (risk reduction 23%; p = 0.16). Fewer patients in the amiodarone group died or were admitted to hospital due to worsening

1994 Lancet Controlled trial quality: uncertain

69. Amiodarone-associated proarrhythmic effects: a review with special reference to torsade de pointes tachycardia

Amiodarone-associated proarrhythmic effects: a review with special reference to torsade de pointes tachycardia Amiodarone-associated proarrhythmic effects: a review with special reference to torsade de pointes tachycardia Amiodarone-associated proarrhythmic effects: a review with special reference to torsade de pointes tachycardia Hohnloser S H, Klingenheben T, Singh B N Authors' objectives To assess the incidence of amiodarone-mediated aggravation of ventricular tachyarrhythmias (...) or the development of new arrhythmias, in particular torsade de pointes. Searching MEDLINE and Current Contents (Clinical Medicine) were searched from 1973 to June 1993 for English language papers, using keywords such as 'amiodarone', 'torsade de pointes', 'proarrhythmia' and 'aggravation of arrhythmia'. Manual searches of references in review articles were performed similarly. Study selection Study designs of evaluations included in the review Case reports, retrospective studies with at least 50 patients

1994 DARE.

70. Adjuvant xamoterol or metoprolol in patients with malignant ventricular arrhythmia resistant to amiodarone. (Abstract)

Adjuvant xamoterol or metoprolol in patients with malignant ventricular arrhythmia resistant to amiodarone. In a randomised cross-over study, six patients with recurrent sustained ventricular tachycardia (VT) were treated with 3 regimens--amiodarone, amiodarone plus metoprolol, and amiodarone plus xamoterol. All patients had poor left ventricular function and were resistant to multiple drugs. Xamoterol (a partial beta-agonist) was more effective than metoprolol as adjuvant therapy to amiodarone (...) in the control of recurrent sustained ventricular arrhythmias and was not associated with any clinical deterioration of ventricular function. Xamoterol was also more effective than metoprolol for suppression of VT at programmed stimulation and as effective as metoprolol for suppression of VT on exercise. Exercise tolerance was significantly greater during treatment with xamoterol/amiodarone than during treatment with metoprolol/amiodarone or with amiodarone alone.

1989 Lancet Controlled trial quality: uncertain

71. Pyridoxine and amiodarone-induced photosensitivity. (Abstract)

Pyridoxine and amiodarone-induced photosensitivity. 3890657 1985 07 24 2015 11 19 0003-4819 103 1 1985 Jul Annals of internal medicine Ann. Intern. Med. Pyridoxine and amiodarone-induced photosensitivity. 68-9 Mulrow J P JP Mulrow C D CD McKenna W J WJ eng Clinical Trial Journal Article Randomized Controlled Trial United States Ann Intern Med 0372351 0003-4819 0 Benzofurans 0 Placebos KV2JZ1BI6Z Pyridoxine N3RQ532IUT Amiodarone AIM IM Adult Aged Amiodarone adverse effects Benzofurans adverse

1985 Annals of Internal Medicine Controlled trial quality: uncertain